within Pharmacolibrary.Drugs.ATC.L;

model L04AC19
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.4166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00346,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00266,
    k12             = 0.379,
    k21             = 0.379
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AC19</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Satralizumab is a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor. It is used as an immunosuppressive agent for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disorder. Satralizumab is approved for use in several countries and is administered to reduce relapse rates in NMOSD patients.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from adult patients with NMOSD administered subcutaneous satralizumab. Model corresponds to population PK analysis in clinical trials, mostly female, mean age approx. 42 years.</p><h4>References</h4><ol><li><p>Bennett, JL, et al., &amp; Pittock, SJ (2023). SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab. <i>Frontiers in neurology</i> 14 1114667–None. DOI:<a href=\"https://doi.org/10.3389/fneur.2023.1114667\">10.3389/fneur.2023.1114667</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36873431/\">https://pubmed.ncbi.nlm.nih.gov/36873431</a></p></li><li><p>Lee, ST, et al., &amp; Gelfand, JM (2024). Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO). <i>Frontiers in neurology</i> 15 1437913–None. DOI:<a href=\"https://doi.org/10.3389/fneur.2024.1437913\">10.3389/fneur.2024.1437913</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39193150/\">https://pubmed.ncbi.nlm.nih.gov/39193150</a></p></li><li><p>Leisegang, R, et al., &amp; Plan, EL (2024). Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a hidden Markov model. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 13(12) 2171–2184. DOI:<a href=\"https://doi.org/10.1002/psp4.13230\">10.1002/psp4.13230</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39380259/\">https://pubmed.ncbi.nlm.nih.gov/39380259</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AC19;
